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Abstract
Background: In thalassemia major (TM), severe cardiac siderosis can be treated by continuous parenteral
deferoxamine, but poor compliance, complications and deaths occur. Combined chelation therapy with
deferiprone and deferoxamine is effective for moderate myocardial siderosis, but has not been
prospectively examined in severe myocardial siderosis.
Methods: T2* cardiovascular magnetic resonance (CMR) was performed in 167 TM patients receiving
standard subcutaneous deferoxamine monotherapy, and 22 had severe myocardial siderosis (T2* < 8 ms)
with impaired left ventricular (LV) function. Fifteen of these patients received combination therapy with
subcutaneous deferoxamine and oral deferiprone with CMR follow-up.
Results: At baseline, deferoxamine was prescribed at 38 ± 10.2 mg/kg for 5.3 days/week, and deferiprone
at 73.9 ± 4.0 mg/kg/day. All patients continued both deferiprone and deferoxamine for 12 months. There
were no deaths or new cardiovascular complications. The myocardial T2* improved (5.7 ± 0.98 ms to 7.9
± 2.47 ms; p = 0.010), with concomitant improvement in LV ejection fraction (51.2 ± 10.9% to 65.6 ± 6.7%;
p < 0.001). Serum ferritin improved from 2057 (CV 7.6%) to 666 (CV 13.2%) μg/L (p < 0.001), and liver
iron improved (liver T2*: 3.7 ± 2.9 ms to 10.8 ± 7.3 ms; p = 0.006).
Conclusion: In patients with severe myocardial siderosis and impaired LV function, combined chelation
therapy with subcutaneous deferoxamine and oral deferiprone reduces myocardial iron and improves
cardiac function. This treatment is considerably less onerous for the patient than conventional high dose
continuous subcutaneous or intravenous deferoxamine monotherapy, and may be considered as an
alternative. Very prolonged tailored treatment with iron chelation is necessary to clear myocardial iron,
and alterations in chelation must be guided by repeated myocardial T2* scans.
Trial registration: This trial is registered as NCT00103753
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Introduction
Globally, there are at least 60,000 individuals born with
thalassemia major (TM) each year [1]. Regular blood
transfusions are mandatory for long term survival, but
over a period of years these cause a secondary state of tis-
sue iron overload. Myocardial iron deposition can result
in cardiomyopathy, and heart failure remains the leading
cause of death [2-4]. The introduction of the iron chelator
deferoxamine greatly ameliorates the effects of iron toxic-
ity, but long-term cardiac mortality has been very disap-
pointing [3,5]. The ongoing deaths from cardiac iron
loading may relate to inadequate compliance or genetic
factors related to metal transporters not yet fully eluci-
dated [6-8], but whatever the cause, there is strong evi-
dence that long-term deferoxamine chelation does not
effectively prevent myocardial siderosis in a majority of
patients [9,10]. Deferiprone, the first approved oral chela-
tor, has been shown in randomized controlled trials to be
effective monotherapy at 100 mg/kg/day in treating mild
to moderately severe myocardial iron loading (myocar-
dial T2* 8–20 ms), significantly improving both myocar-
dial iron and ejection fraction [11], and the combination
of deferiprone at 75 mg/kg/day with deferoxamine is like-
wise effective [12]. However greater total iron clearance is
seen with combined treatment [13-15], which suggests
that it might be useful for severe myocardial siderosis
(T2* < 10 ms).
The conventional treatment at many centers for severe
myocardial siderosis with heart failure is long-term, con-
tinuous, high-dose intravenous deferoxamine. Several
small studies have confirmed that this approach is effec-
tive, and reversal of cardiomyopathy is possible [16,17].
However, deaths still occur, complications such as infec-
tion and thrombosis are common, and poor compliance
with these demanding regimes is problematic [16]. Com-
bined chelation therapy in this situation might be effec-
tive, yet prospective trials examining the treatment of
severe cardiac siderosis are lacking. Cardiovascular mag-
netic resonance (CMR) permits highly reproducible meas-
urements of myocardial iron loading (T2*) [18,19], and
ventricular function [20,21], making this modality ideally
suited to assessing cardiovascular response to chelation
treatments in TM [9-12]. Therefore, we prospectively
examined the effects of combination therapy in TM
patients with severe myocardial siderosis.
Methods
Study protocol
As part of a previously reported randomized controlled
trial investigating the combined therapy of deferoxamine
and deferiprone in mild-moderate myocardial siderosis
[12], 167 adult patients (75 males, 30 ± 5.3 years) with
TM were screened for quantification of myocardial iron
loading using myocardial T2* [10]. These subjects were
recruited from 12 centers in Sardinia, Italy. The inclusion
criteria for patient screening were: diagnosis of beta-tha-
lassemia major currently maintained on subcutaneous
deferoxamine monotherapy; age >18 years; maintaining
pre-transfusion hemoglobin > 9 g/dL. Exclusion criteria
were: Patients who had previously received deferiprone
for a total of more than 6 months over the last 5 years;
patients with previous reaction to deferiprone; neutrope-
nia (ANC <1.5 × 109/L) at screening; thrombocytopenia
(<50 × 109/L) at screening; liver enzymes > 3 times upper
limit of normal; and implant incompatible with MR (such
as pacemaker), or other condition making CMR impossi-
ble or inadvisable (e.g. claustrophobia).
Of the 167 patients screened, 108 (65%) had significant
myocardial siderosis (T2* < 20 ms), of whom 22 (13%)
had severe myocardial loading (T2* < 8 ms) [10]. Patients
with severe cardiac siderosis (T2* < 8 ms) were not rand-
omized into the randomized controlled trial in accord
with the study protocol, and it was at the treating clini-
cian's discretion to determine best clinical practice chela-
tion therapy. The threshold of 8 ms was set in accord with
practice at the time of approval of the protocol by the eth-
ics committee, although a myocardial T2* of 10 ms is typ-
ically considered the contemporary threshold for defining
severe myocardial iron loading. We prospectively studied
those patients with severe myocardial siderosis who
received combination chelation therapy (deferiprone plus
deferoxamine). The study protocol was approved by Eth-
ics committees in London and Cagliari. Patient informa-
tion and consent forms were in Italian and all patients
gave written informed consent. The authors had full
access to the data and took responsibility for its integrity.
All authors have read and agree to the manuscript as writ-
ten.
Study patients
Of the 22 patients with severe myocardial siderosis, 15 (9
female, 28.9 ± 4.8 years) received unblinded combination
therapy according to locally developed protocols, and
were followed prospectively. These 15 patients form the
subject of this paper. All 15 patients (100%) had impaired
left ventricular systolic function relative to published nor-
mal values for thalassemia patients without myocardial
iron loading [22]. Of the remaining 7 subjects, 3 subjects
received intensive monotherapy with deferoxamine, 1
patient received deferiprone monotherapy, and in 3
patients treatment was maintained at local centers outside
the study and were not included. One patient who was
maintained on deferoxamine monotherapy died of cir-
rhotic liver disease.
In the 15 study patients, 9 (60%) had a prior history of
heart failure, and all 9 were taking cardiac medications
(angiotensin converting enzyme (ACE) inhibitor ± diu-Journal of Cardiovascular Magnetic Resonance 2008, 10:12 http://www.jcmr-online.com/content/10/1/12
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retic). Two of these subjects were in decompensated con-
gestive cardiac failure at the time of screening. At baseline,
1 of the patients with symptomatic heart failure was in
atrial flutter. The remaining 14 subjects were in sinus
rhythm. At baseline, all patients were being maintained
on subcutaneous deferoxamine monotherapy (no patient
was receiving deferiprone) with a mean dose of 38 mg/kg
for 5.3 days/week (equivalent to 40.3 mg/kg/d for 5 days/
week). This is comparable to the 40–50 mg/kg/day for 5
days/week from clinical recommendations for routine
practice [23].
Efficacy and safety assessments
A UK-based mobile CMR scanner (1.5 Tesla, Sonata, Sie-
mens, Erlangen, Germany) was transported on 3 occa-
sions to Cagliari, Sardinia. The 15 patients on
combination therapy underwent CMR assessments at
baseline, 6 and 12 months to assess myocardial and
hepatic iron loading (T2*), left ventricular (LV) volumes,
and ejection fraction (EF). Myocardial and hepatic T2*
were assessed using the single breath-hold multi-echo
technique [24], with bright blood [25]. T2* analysis was
performed using Thalassemia-Tools (a plug-in of CMR-
tools, Cardiovascular Imaging Solutions, London, UK) as
described previously [24]. Ventricular volumes were
determined using steady state free precession cines, with
contiguous short axis slices from base to apex [26]. Ven-
tricular volumes were also analyzed using CMRtools. As
LV volumes and mass vary with height and weight these
were indexed to body surface area (BSA). Other laboratory
measures included weekly full blood count (risk of agran-
ulocytosis with deferiprone), serum ferritin (Abbott
AXSYM System), B-type natriuretic peptide (BNP-Biosite
Diagnostics Inc, San Diego, California), and liver function
tests (alanine aminotransferase [ALT]).
Statistical analysis
Trend analysis over time for continuous parameters with
normal distribution was performed using repeated meas-
ures ANOVA. Where the ANOVA was significant, the
changes in parameters between time points were further
analyzed using Least Significant Difference post-hoc test-
ing. The Shapiro-Wilk test of normality identified BNP
and serum ferritin as having non-parametric distribu-
tions. Serum ferritin levels demonstrated a positively
skewed distribution and were subsequently log trans-
formed to achieve normality. In the case of BNP measure-
ments analysis was performed by Kruskal-Wallis testing.
T2* and other parameters did not deviate significantly
from normal in this study. Summary data are presented as
mean ± standard deviation (SD), except ferritin data
which are presented using the geometric mean (the anti-
log of the mean in log scale) ± the coefficient of variation
(CV, equivalent to the variance of the mean in log scale).
Statistical analysis was performed using SPSS Version 10.0
(SPSS, Inc, Chicago, Illinois). A p-value of 0.05 was the
threshold used for statistical significance.
Results
Patient Characterization
There were no subject withdrawals with all 15 patients
continuing with the combined chelation therapy for the
Table 1: 
Age (years) 28.9 ± 4.8
Gender
Male (M) 6
Female (F) 9
Body Surface Area (m2) 1.56 ± 0.1
Deferoxamine dose (mg/kg) 38 ± 10.2
5.3 days/week
CMR measures:
Myocardial T2* (ms) [>20] 5.7 ± 1.0
Liver T2* (ms) [>19] 3.7 ± 2.9
LV end diastolic volume index (mL/m2) [M:45–152, F:54–121] 87.1 ± 31.6
LV end systolic volume index (mL/m2) [M:13–34, F:6–35] 44.4 ± 24.9
LV ejection fraction (%) [M > 59%; F > 63%] 51.2 ± 10.9
Blood measures:
Transfusional red blood cell input (mL/kg/year) 155.1 ± 40.9
Mean year hemoglobin (g/dL) 11.0 ± 1.2
Hepatitis C positive
Yes 14
No 1
Biochemistry
Serum ferritin (μg/L) [M: 5–104, F: 4–254 ] 2057 ± 7.6
Alanine aminotransferase (IU/L) [5-35] 53.4 ± 34.8
BNP (pmol/L) [<100] 26.0 (9.8–758)
Serum creatinine (mg/dL) [0.6–1.2] 0.68 ± 0.19Journal of Cardiovascular Magnetic Resonance 2008, 10:12 http://www.jcmr-online.com/content/10/1/12
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full 12 months duration of the study. Baseline patient
characteristics are given in table 1. During the study
period, patients received combined chelation therapy for
a mean of 11.7 ± 1.6 months.
Iron chelation
The dose of deferoxamine prescribed at baseline was 38.0
± 10.2 mg/kg for 5.3 days/week. At the end of 12 months
the prescribed dose had been reduced to 20.3 ± 10.9 for
4.5 days/week (p < 0.001). This dosing decrease reflects
the standard clinical practice of dose reduction of deferox-
amine in subjects with substantial falls in serum ferritin to
minimize toxicity. The starting dose of deferiprone pre-
scribed was 73.9 ± 4.0 mg/kg/day for 7 days per week. At
12 months, this had been decreased to 65.7 ± 10.7 mg/kg/
day (p = 0.01), with dose reduction necessary in some
patients due to mild adverse events (gastro-intestinal
symptoms). All patients received both deferiprone and
deferoxamine throughout the study period.
Myocardial and hepatic iron
Myocardial T2* improved significantly from baseline 5.7
± 0.98 ms to 7.1 ± 1.96 ms at 6 months, and 7.9 ± 2.47 ms
at 12 months (ANOVA p = 0.010; figure 1, table 2). Liver
T2* improved significantly from a baseline of 3.7 ± 2.9 ms
to 8.8 ± 6.4 ms at 6 months, and 10.8 ± 7.3 ms at 12
months (ANOVA p = 0.006; figure 2).
Cardiac function and volumes
There was a significant improvement in LVEF over 12
months, increasing from 51.2 ± 10.9% at baseline to 65.6
± 6.7% at 12 months (ANOVA p < 0.001, figure 3, Table
2). End systolic volume index (ESVI) decreased signifi-
cantly, from a baseline value of 44.4 ± 24.9 mL/m2 to 29.3
± 11.1 mL/m2 at 12 months (ANOVA p = 0.043, figure 4).
There was a non-significant change in end diastolic vol-
ume index (EDVI) from a baseline of 87.1 ± 31.6 mL/m2
to 83.5 ± 17.4 mL/m2 at 12 months (p = 0.72). LV mass
index did not change significantly (baseline 85.2 ± 14.2 g/
m2; 12 months, 83.9 ± 14.4 g/m2, p = 0.93).
Serum Ferritin
There was a significant reduction in ferritin, from 2057
μg/L (CV 7.6%) at baseline to 666 μg/L (CV 13.2%) at 12
months (ANOVA p < 0.001; figure 5).
BNP
Only 2 patients at baseline had elevated BNP levels (>100
pmol/l), and both these patients were in overt cardiac fail-
ure. The BNP levels normalized within 6 months. Over 12
months there was no significant change in BNP in the
whole group (26.0 to 21.6 pmol/l over 12 months, p =
0.56).
Myocardial T2* improved significantly between baseline and  12 months Figure 1
Myocardial T2* improved significantly between base-
line and 12 months. Standard error bars are shown. The p 
values shown are post-hoc analyses for 0–6 months, and 0–
12 months.
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Liver T2* improved significantly between baseline and 12  months Figure 2
Liver T2* improved significantly between baseline 
and 12 months. Standard error bars are shown. The p val-
ues shown are post-hoc analyses for 0–6 months, and 0–12 
months.
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Cardiac complications and medication
At baseline, 2 patients were in overt cardiac failure (sub-
jects 5 and 8, table 2). One of these patients was also in
atrial flutter. This patient was briefly hospitalized for ino-
tropic support (dopamine), diuresis, and commencement
of combination therapy, and subsequently made a steady
recovery, reverting to sinus rhythm with no further cardiac
complications during the study period. The other patient
in heart failure responded to diuresis and continued ACE
inhibition, and did not require inotropic support. There
were no other cardiac complications in the remaining 13
patients. During the trial period no new cardiac medica-
tions were commenced in any of these 13 patients.
Adverse events
There were no episodes of neutropenia or agranulocytosis.
The most commonly reported side effects were mild gas-
tro-intestinal symptoms (4/15 (27%)). There was one
case of mild transient arthralgia, and one case of transient
elevation of ALT (deferiprone was continued).
Discussion
Heart failure secondary to myocardial iron loading
remains the single most important cause of death in
patients with TM [2,3]. It is well recognized that LV dys-
function and symptomatic heart failure occur at an
advanced stage of cardiac siderosis, at which point treat-
ment can be difficult and there is a poor prognosis
[27,28]. Non-continuous deferoxamine monotherapy
appears to be inadequate in such patients [29,30]. Inten-
sive, continuous intravenous deferoxamine is probably
more effective, and reverses cardiomyopathy in many, but
not all cases [16,17], and many centers consider this (or
continuous subcutaneous infusion [31]) to be the stand-
ard of care. Combined therapy with deferoxamine and
deferiprone has been demonstrated to be of clear benefit
in the treatment of cardiac siderosis in TM [12,13,32,33],
but the role of combined therapy in the management of
severe cardiac siderosis has not been specifically
addressed beyond a few case reports [34-36] yet it has
potential advantages over standard intensive intravenous
chelation. Firstly, the presence of a long-term intravenous
central catheter is not required which obviates the attend-
ant risks (including infection and thrombosis). Secondly,
the risk of deferoxamine toxicity might be reduced
through the lower doses used in combined therapy.
Thirdly, the use of intermittent subcutaneous deferoxam-
ine therapy is less disruptive to patients and could confer
improved compliance, which is considered a key factor in
improving mortality in TM [16,37]. Finally, there is sub-
stantial evidence to suggest that deferiprone has superior
cardioprotective effects [4,11,38,39], which remain to be
fully explained, but anti-oxidant effects and influence on
iron transport mechanisms are possibilities [6-8].
This study demonstrates that combined therapy in
patients with severe cardiac siderosis results in large and
significant improvements in myocardial iron loading and
There was a significant improvement in LV ejection fraction  over 12 months Figure 3
There was a significant improvement in LV ejection 
fraction over 12 months. Standard error bars are shown. 
The p values shown are post-hoc analyses for 0–6 months, 
and 0–12 months.
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LV end-systolic volume index decreased significantly over 12  months Figure 4
LV end-systolic volume index decreased significantly 
over 12 months. Standard error bars are shown. The p val-
ues shown are post-hoc analyses for 0–6 months, and 0–12 
months.
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ventricular function. In all cases bar one, an improvement
in myocardial T2* was coupled with an improvement in
ejection fraction. In this one case, the apparent lack of
improvement in cardiac function might reflect unknown
biological factors, or measurement error. Despite compa-
rable chelation regimes, some subjects showed far greater
improvements in myocardial iron clearance and cardiac
function compared to others. Although not formally
assessed in this study, the degree of compliance to the pre-
scribed chelation dose is likely to account for the majority
of these observed differences. Other factors that might
play a role in determining response to therapy include
individual variation in chelation metabolism, or genetic
factors involved in the regulation of myocardial iron
metabolism. Clearance of iron from the heart is slow with
all treatments in severe cardiac siderosis however, and
treatment for 12 months is clearly inadequate to clear the
cardiac iron, indicating that changes in chelation tailored
to the cardiac siderosis must be guided by repeated cardiac
T2* measurements. It would appear from the current trial
that treatment of these patients would be necessary at the
same chelation intensity for approximately 3–4 years to
raise the T2* above 20 ms (assuming that the rate of clear-
ance is constant). During this period the liver iron and fer-
ritin will become low, and one clear advantage of the
combination regime is that the likelihood of adverse
effects of deferoxamine in these circumstances can be
ameliorated through appropriate dose reduction (20.3
mg/kg for 4.5 days per week at the end of 12 months treat-
ment in this study).
The rate of clearance of myocardial iron in the current trial
of combination therapy (5.7 to 7.9 ms) was similar to that
reported in a previous prospective study by Anderson who
reported the changes in myocardial T2* in patients pre-
senting with heart failure due to cardiac siderosis in
response to high dose 24 hour per day intravenous defer-
oxamine for 12 months (5.1 to 8.1 ms) [17]. In both these
studies, there were impressive improvements in ejection
fraction (current study +14.4%; Anderson's study +11%)
from a similar baseline (current study 51.2%; Anderson's
study 52.0%). This emphasizes the relatively high value of
Table 2: 
Subject Sex Baseline NYHA Heart Failure Class BASELINE 12 MONTHS
Myocardial T2* (ms) LVEF (%) Myocardial T2* (ms) LVEF (%)
1 F I 5.2 59 6.2 70
2 M I 6.0 28 6.4 57
3 M I 6.5 50 10.0 68
4 M I 6.4 42 9.2 63
5 M II 5.6 30 6.1 47
6 M I 5.0 57 5.4 73
7 F I 4.8 60 5.5 74
8 F III 5.3 43 7.6 67
9 F I 5.0 54 8.1 67
10 M I 5.7 58 6.6 67
11 F I 5.4 49 10.4 66
12 F I 7.3 61 11.5 70
13 F I 3.7 61 4.8 61
14 F I 7.4 60 13.2 65
15 F I 6.1 56 7.1 69
There was a significant reduction in serum ferritin over 12  months Figure 5
There was a significant reduction in serum ferritin 
over 12 months. The vertical axis shows the geometric 
mean of ferritin. Standard error bars are shown. The p values 
shown are post-hoc analyses for 0–6 months, and 0–12 
months.
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ejection fraction at which patients with TM develop heart
failure compared to patients with coronary disease and
cardiomyopathy. Recently, the normal reference range for
LV volumes and function in TM without myocardial iron
have been determined by CMR [22]. An adaptive response
to their chronic anemic state and other factors produces a
hyperdynamic circulation, resulting in significantly differ-
ent LV parameters as compared with normal controls. The
mean LV ejection fraction is therefore significantly
increased in TM patients, with the mean measured by
CMR for women being 75.1 ± 5.9%, and men 71.0% ±
6.1%. These are 6–8% absolute units higher than normal
subjects and indicate that TM patients have impaired LV
function at higher values of LV ejection fraction than pre-
viously thought. Improvements in ejection fraction were
mediated via a reduction in end systolic volume, with end
diastolic volume not being significantly changed. This
reflects no change in volume loading, but an improve-
ment in contractility.
These results also demonstrate that following the addition
of deferiprone, the total weekly deferoxamine dose and
infusion frequency can be significantly reduced without
compromising myocardial iron loading and function. The
incidence of adverse effects was low and consistent with
prior studies of these chelators. A recent prospective study
has demonstrated that twice weekly deferoxamine infu-
sions in conjunction with deferiprone five times per week,
shows similar efficacy to standard deferoxamine mono-
therapy in removing iron [40]. A reduction in intensity of
deferoxamine chelation is likely to confer considerable
benefits to the patient. In Anderson's study, where much
higher doses of continuous deferoxamine were used
(mean dose 46 mg/kg/day, 7 days/week), neuro-toxicity
was documented in two-thirds of patients. No cases of
deferoxamine toxicity were reported in this study. The
reduced dose frequency seen in the current study (4.5
days/week at 12 months) is likely to be more convenient
to patients and potentially improve compliance.
This study addresses a number of other issues regarding
the management of cardiac siderosis in TM. CMR tech-
niques have recently illuminated the weak relation
between liver iron/ferritin, and myocardial siderosis
[10,41,42]. This has challenged existing opinion that sur-
vival without cardiac disease is good where serum ferritin
levels and liver iron remain below 2500 μg/l and 15 mg/
g/dry weight, respectively [2,43-45]. The 3-year mean fer-
ritin levels, and baseline liver iron concentrations of this
cohort are given in table 3. The vast majority of these
patients with severe cardiac siderosis would have been
considered at low risk of cardiac complications on the
basis of traditional static ferritin and liver iron concentra-
tion based thresholds. Yet all these subjects demonstrated
LV dysfunction at baseline. Both subjects with decompen-
sated heart failure had 3 year mean ferritin levels <2500
μg/L, and baseline liver iron concentration <15 mg/g/dry
weight. These findings highlight the difficulties in using
such surrogate parameters to guide cardiac management.
BNP has been found to have diagnostic and prognostic
use in non-siderotic heart failure [46,47], but data regard-
ing its application in thalassemia is sparse [10]. In this
cohort, only the 2 subjects in overt cardiac failure had
abnormal BNP levels. This suggests that BNP levels
become raised only at a very advanced stage, and are
therefore unlikely to contribute significantly to the pre-
clinical identification of siderotic cardiomyopathy. The
lack of significant change in BNP over 12 months (in the
whole group) despite considerable improvements in car-
diac function and cardiac siderosis also suggests little role
for serial BNP measurements in these patients. It is possi-
Table 3: 
Subject Mean 3 year ferritin (μg/L) Liver T2* (ms) Liver Iron Concentration (mg/g/dry weight)
1 2297 1.5 9.3
2 1135 3.0 4.4
3 1273 1.9 7.1
4 1211 8.4 1.5
5 2342 1.9 7.1
6 1400 1.7 8.2
7 3667 0.95 15.2
8 2442 1.2 11.8
9 1867 4.1 3.2
10 1957 3.9 3.4
11 500 1.6 8.6
12 967 11.2 1.1
13 2835 3.2 4.2
14 1250 5.0 2.6
15 1536 5.9 2.2Journal of Cardiovascular Magnetic Resonance 2008, 10:12 http://www.jcmr-online.com/content/10/1/12
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ble that an explanation for this finding is that BNP secre-
tion is impaired in cardiac siderosis (cardiac
endocrinopathy).
Limitations
This study was limited by the relatively low number of
patients and its non-comparative nature. This precludes
definitive conclusions about the relative efficacy as com-
pared to continuous intravenous deferoxamine therapy
for the treatment of severe cardiac siderosis. However, the
findings of improved myocardial iron loading and cardiac
function mimic those recently demonstrated in the larger
randomized controlled trial in patients with mild-moder-
ately severe cardiac siderosis [12], suggesting that combi-
nation therapy is also effective in this patient group.
Conclusion
Combined chelation therapy in patients with severe car-
diac siderosis is well tolerated, and effective in removing
myocardial iron and improving ventricular function.
These findings suggest that this therapy may be consid-
ered as an alternative to continuous subcutaneous or
intravenous deferoxamine in the management of these
patients.
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